𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Type 1 hepatorenal syndrome in cirrhosis. Predictive factors forsurvival in patients treated with terlipressin

✍ Scribed by F. Durand; I. Colle; F. Pessione; J. Bernuau; E. Barrière; D. Lebrec; D.C. Valla; R. Moreau

Book ID
119525910
Publisher
Elsevier Science
Year
2000
Tongue
English
Weight
145 KB
Volume
32
Category
Article
ISSN
0168-8278

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Predictors of response to therapy with t
Predictors of response to therapy with terlipressin and albumin in patients with cirrhosis and type 1 hepatorenal syndrome
✍ André Nazar; Gustavo Henrique Pereira; Mónica Guevara; Marta Martín-Llahi; Marie 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 169 KB 👁 1 views

Terlipressin plus albumin is an effective treatment for type 1 hepatorenal syndrome (HRS), but approximately only half of the patients respond to this therapy. The aim of this study was to assess predictive factors of response to treatment with terlipressin and albumin in patients with type 1 HRS. T

Terlipressin improves renal function in
Terlipressin improves renal function in patients with cirrhosis and ascites without hepatorenal syndrome
✍ Aleksander Krag; Søren Møller; Jens H. Henriksen; Niels-Henrik Holstein-Rathlou; 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 200 KB 👁 1 views

Patients with advanced cirrhosis and ascites are characterized by circulatory dysfunction with splanchnic vasodilatation and renal vasoconstriction, which often lead to ascites. The vasoconstrictor terlipressin improves renal function in hepatorenal syndrome (HRS). The aim of this study was to evalu